CNTNAP2 and encephalitis: Overall, 25 (9.84%) patients experienced recurrence, including 16 patients with anti-NMDAR encephalitis, 6 anti-LGI1encephalitis, 1 anti-GABABR encephalitis, 1 anti-CASPR2 encephalitis, and 1 anti-AMPAR (type 2) encephalitis.